Panacea Life Sciences Holdings, Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.4M | $1.6M | $2.1M | $9.0M | $345.7K | $0 | $0 |
| Cost of Revenue | — | $1.3M | $1.2M | $1.5M | $7.0M | $1.9M | $0 | — |
| Gross Profit | — | $1.1M | $396.5K | $540.6K | $2.0M | $-1.7M | $0 | — |
| Gross Margin | — | 47.0% | 24.4% | 26.2% | 22.2% | -491.9% | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $0 | $22.1K | $300.0K | $356.1K |
| SG&A Expense | — | $1.5M | $1.1M | $1.5M | $2.8M | $2.8M | $1.9M | $1.2M |
| Operating Income | — | $-5.5M | $-5.7M | $-5.9M | $-5.3M | $-10.7M | $-2.4M | $-3.1M |
| Operating Margin | — | -232.5% | -347.4% | -288.3% | -58.3% | -3,087.5% | — | — |
| Interest Expense | — | $1.6M | $2.0M | $1.1M | $1.5M | $479.1K | $464.5K | $68.6K |
| Pretax Income | — | $-8.0M | $-9.1M | $-4.8M | $-5.2M | $-10.0M | $-4.3M | $-3.9M |
| Income Tax Expense | — | — | — | — | — | — | $0 | $0 |
| Net Income | — | $-8.0M | $-9.1M | $-4.8M | $-5.2M | $-10.0M | $-4.3M | $-3.9M |
| Net Margin | — | -336.1% | -561.9% | -232.2% | -58.0% | -2,898.3% | — | — |
| EPS (Basic) | — | $-0.48 | $-0.62 | $-0.28 | $-0.31 | $-0.30 | $-0.91 | $-0.91 |
| EPS (Diluted) | — | $-0.48 | $-0.62 | $-0.27 | $-0.31 | $-0.30 | $-0.91 | $-0.91 |
| Shares Outstanding (Basic) | 17.6M | 16.6M | 14.9M | 16.9M | 16.9M | 43.8M | 6.2M | 4.4M |
| Shares Outstanding (Diluted) | 17.6M | 16.6M | 14.9M | 16.9M | 16.9M | 43.8M | 6.2M | 4.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |